Equities research analysts expect that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will report earnings per share of $1.08 for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Alexion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $1.05 and the highest estimate coming in at $1.11. Alexion Pharmaceuticals reported earnings of $0.93 per share in the same quarter last year, which suggests a positive year over year growth rate of 16.1%. The business is scheduled to announce its next quarterly earnings report on Thursday, July 27th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year earnings of $4.54 per share for the current financial year, with EPS estimates ranging from $4.44 to $4.77. For the next financial year, analysts expect that the company will post earnings of $5.49 per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.33. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The firm had revenue of $870 million during the quarter, compared to the consensus estimate of $826.63 million. During the same quarter in the prior year, the company earned $1.11 EPS. The firm’s revenue for the quarter was up 24.3% compared to the same quarter last year.

A number of brokerages have weighed in on ALXN. Stifel Nicolaus reissued a “buy” rating and set a $157.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Jefferies Group LLC set a $120.00 price target on Alexion Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, June 8th. Royal Bank Of Canada reissued an “outperform” rating and set a $177.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, March 27th. Barclays PLC reissued an “overweight” rating and set a $155.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 9th. Finally, Morgan Stanley reissued an “overweight” rating and set a $138.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $161.38.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the business’s stock in a transaction on Wednesday, June 14th. The stock was purchased at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.35% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in Alexion Pharmaceuticals by 13.4% in the fourth quarter. FMR LLC now owns 28,168,163 shares of the biopharmaceutical company’s stock valued at $3,446,375,000 after buying an additional 3,338,382 shares during the last quarter. BlackRock Inc. boosted its stake in Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares during the last quarter. Vanguard Group Inc. boosted its stake in Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock valued at $1,754,034,000 after buying an additional 433,293 shares during the last quarter. State Street Corp boosted its stake in Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock valued at $1,166,682,000 after buying an additional 1,309,529 shares during the last quarter. Hedge funds and other institutional investors own 94.38% of the company’s stock.

Shares of Alexion Pharmaceuticals (ALXN) traded down 3.39% during mid-day trading on Wednesday, reaching $113.98. The company had a trading volume of 4,622,346 shares. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $145.42. The company has a market capitalization of $25.59 billion, a price-to-earnings ratio of 54.30 and a beta of 1.45. The firm’s 50-day moving average is $113.46 and its 200 day moving average is $122.45. Alexion Pharmaceuticals also was the recipient of unusually large options trading on Wednesday. Investors acquired 1,630 call options on the company. This is an increase of approximately 549% compared to the typical daily volume of 251 call options.

ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/07/16/alexion-pharmaceuticals-inc-alxn-expected-to-post-earnings-of-1-08-per-share-updated-updated-updated.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.